Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites
Siennah R. Miller, Meghan E. McGrath, Kimberley M. Zorn, et al.
Molecular Pharmacology (2021) Vol. 100, Iss. 6, pp. 548-557
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Molnupiravir: A new candidate for COVID‐19 treatment
Fariba Pourkarim, Samira Pourtaghi‐Anvarian, Haleh Rezaee
Pharmacology Research & Perspectives (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 108
A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants
Ching‐Wen Chang, Krishna Mohan Parsi, Mohan Somasundaran, et al.
Viruses (2022) Vol. 14, Iss. 7, pp. 1369-1369
Open Access | Times Cited: 39
Molnupiravir: Mechanism of action, clinical, and translational science
Brian M. Maas, Julie Strizki, Randy R. Miller, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 2
Open Access | Times Cited: 7
A path from synthesis to emergency use authorization of molnupiravir as a COVID-19 therapy
Norein Sakander, Ajaz Ahmed, Mahir Bhardwaj, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107379-107379
Closed Access | Times Cited: 3
Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
Daisy Yan, Bingfang Yan
Fundamental and Clinical Pharmacology (2023) Vol. 37, Iss. 4, pp. 726-738
Open Access | Times Cited: 10
Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier
Chun‐Hao Chang, Wen-Ya Peng, Wan-Hsin Lee, et al.
EBioMedicine (2023) Vol. 95, pp. 104748-104748
Open Access | Times Cited: 10
Drug Transporters at the Human Blood-Testis Barrier
Raymond K. Hau, Stephen H. Wright, Nathan J. Cherrington
Drug Metabolism and Disposition (2023) Vol. 51, Iss. 5, pp. 560-571
Open Access | Times Cited: 9
The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro
Yue Shen, William Eades, William Liu, et al.
Drug Metabolism and Disposition (2022) Vol. 50, Iss. 9, pp. 1151-1160
Open Access | Times Cited: 17
Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment
Amy Q. Wang, Natalie R. Hagen, Elias Carvalho Padilha, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro
Katja Merches, Leonie Breunig, Julia Fender, et al.
Archives of Toxicology (2022) Vol. 96, Iss. 8, pp. 2341-2360
Open Access | Times Cited: 15
COVID‐19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples
Chukwunonso K. Nwabufo, Jessica G.Y. Luc, Allison McGeer, et al.
British Journal of Clinical Pharmacology (2024) Vol. 90, Iss. 9, pp. 2137-2158
Open Access | Times Cited: 2
Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19
Hong Zhou, Wei‐Jian Ni, Wei Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients
Raymond K. Hau, Stephen H. Wright, Nathan J. Cherrington
Clinical and Translational Science (2022) Vol. 15, Iss. 7, pp. 1599-1605
Open Access | Times Cited: 13
SARS-CoV-2 rebound with and without antivirals
Nicola Petrosillo
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 637-639
Open Access | Times Cited: 7
Addressing the Clinical Importance of Equilibrative Nucleoside Transporters in Drug Discovery and Development
Raymond K. Hau, Stephen H. Wright, Nathan J. Cherrington
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 4, pp. 780-794
Closed Access | Times Cited: 7
Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat
Chun‐Hao Chang, Wen-Ya Peng, Wan-Hsin Lee, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 5
Computer-aided discovery, design, and investigation of COVID-19 therapeutics
Chun-Chun Chang, Hao‐Jen Hsu, Tien‐Yuan Wu, et al.
Tzu Chi Medical Journal (2022) Vol. 34, Iss. 3, pp. 276-286
Open Access | Times Cited: 8
Transporters and Toxicity: Insights From the International Transporter Consortium Workshop 4
Michael J. Hafey, Lauren M. Aleksunes, Christy C. Bridges, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 112, Iss. 3, pp. 527-539
Closed Access | Times Cited: 8
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T.K. Lau, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 8
The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19
Ana C. Puhl, Thomas R. Lane, Fabio Urbina, et al.
Frontiers in Drug Discovery (2022) Vol. 2
Open Access | Times Cited: 8
Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs
Chukwunonso K. Nwabufo, Reina Bendayan
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 12, pp. 1041-1054
Open Access | Times Cited: 7
An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations
Yusuke Marikawa, Vernadeth B. Alarcón
Reproductive Toxicology (2023) Vol. 121, pp. 108475-108475
Open Access | Times Cited: 3
Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs
Mengbi Yang, Xin Xu
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 7-8, pp. 483-505
Open Access | Times Cited: 6
Inborn Errors of Nucleoside Transporter (NT)-Encoding Genes (SLC28 and SLC29)
Marçal Pastor‐Anglada, Aida Mata-Ventosa, Sandra Pérez‐Torras
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8770-8770
Open Access | Times Cited: 5
Transporter Inhibition Profile for the Antivirals Tilorone, Quinacrine and Pyronaridine
Patricia A. Vignaux, Thomas R. Lane, Ana C. Puhl, et al.
ACS Omega (2023) Vol. 8, Iss. 13, pp. 12532-12537
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top